BeiGene (HKSE:06160) Inventories, Raw Materials & Components : HK$1,148 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BeiGene Inventories, Raw Materials & Components?

BeiGene's inventories, raw materials & components for the quarter that ended in Sep. 2024 was HK$1,148 Mil.

BeiGene's quarterly raw materials declined from Mar. 2024 (HK$1,234 Mil) to Jun. 2024 (HK$1,122 Mil) but then increased from Jun. 2024 (HK$1,122 Mil) to Sep. 2024 (HK$1,148 Mil).

BeiGene's annual raw materials increased from Dec. 2021 (HK$609 Mil) to Dec. 2022 (HK$693 Mil) and increased from Dec. 2022 (HK$693 Mil) to Dec. 2023 (HK$1,162 Mil).

BeiGene Inventories, Raw Materials & Components Historical Data

The historical data trend for BeiGene's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Inventories, Raw Materials & Components Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Raw Materials & Components

Get a 7-Day Free Trial

149.84

609.41

692.57

1,161.88

BeiGene Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Inventories, Raw Materials & Components	Get a 7-Day Free Trial															736.12	1,161.88	1,233.96	1,121.95	1,147.59

BeiGene Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

BeiGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Inventories, Raw Materials & Components

Comparable Companies

Traded in Other Exchanges

BEIGF:USA BGNE:USA 49B:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

Executives

Oyler John Victor	2101 Beneficial owner
Jpmorgan Chase & Co.	2502 Approved lending agent
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Baker Felix James	2201 Interest of corporation controlled by you
Baker Julian Charles	2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc	2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p.	2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd.	2102 Investment manager
Hhlr Fund, L.p.	2101 Beneficial owner
Amgen Inc.	2101 Beneficial owner
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene Headlines

No Headlines